VASOPRESSIN

Post-LOE

vasopressin

Gland Pharma

ANDAINTRAVENOUSSOLUTION

Approved

Feb 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

2/8 — Basic

Drug data last refreshed 1w ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (14)

NCT04789148Phase 1Recruiting

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

Started Sep 2025

40 enrolled

Vasopressin Deficiency

NCT06464510Phase 3Recruiting

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

Started Nov 2024

2,800 enrolled

Septic Shock

NCT05958342Phase 2Recruiting

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Started Jun 2024

1,050 enrolled

TraumaHemorrhage

NCT03204786Phase 2/3Completed

Intranasal Vasopressin Treatment in Children With Autism

Started Feb 2018

157 enrolled

AutismAutism Spectrum DisorderASD

NCT02761434N/ACompleted

The Effect of Vasopressin on Glucose Regulation

Started Apr 2016

60 enrolled

Insulin Resistance

Worked on VASOPRESSIN at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.